Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapy.
BACKGROUND
Premature cardiovascular disease is increasingly recognized in HIV-infected patients, but the mechanisms involved are unclear. The purpose of this study was to determine the impact of HIV infection and antiretroviral therapy (ART) on markers of early vascular disease in children.


RESULTS
We studied 83 HIV-infected children (56 had taken ART, of whom 31 received a regimen containing protease inhibitors [PIs]; 27 were never treated) and a control group of 59 healthy children. Carotid intima-media thickness (IMT) and brachial artery flow-mediated dilatation (FMD) were measured. IMT was significantly greater in HIV-infected children compared with the control subjects (P<0.001). Among the HIV-infected children, age and treatment were significantly associated with increased IMT. Children exposed to PIs had greater IMT compared with both non-PI-treated children and untreated children (P=0.02). FMD was also significantly reduced in the HIV-infected children compared with control subjects (P=0.02). Pairwise comparisons of different treatment exposure groups revealed that FMD was impaired by a mean of 3.6% (95% CI, 1.8 to 5.3; P<0.001) for children exposed to PIs compared with untreated children and by a mean of 1.8% (95% CI, 0.01 to 3.5; P=0.05) compared with non-PI-treated children. HIV-infected children had lipid abnormalities, but they did not account for the observed differences in either FMD or IMT.


CONCLUSIONS
HIV infection in childhood is associated with adverse structural and functional vascular changes that are most pronounced in children exposed to PI therapy. Longitudinal studies are required to differentiate the relative impact of HIV disease and ART and to assess the potential for prevention.
Vascular Physiology Unit, Institute of Child Health, London, UK. charakidadoc@hotmail.com
Marietta
M
Charakida
Ann E
AE
Donald
Hannah
H
Green
Clare
C
Storry
Margaret
M
Clapson
Muriel
M
Caslake
David T
DT
Dunn
Julian P
JP
Halcox
Diana M
DM
Gibb
Nigel J
NJ
Klein
John E
JE
Deanfield
D000293:Adolescent; D044966:Anti-Retroviral Agents / Q000009:adverse effects; D015415:Biomarkers / Q000032:analysis; D001837:Body Weights and Measures; D016022:Case-Control Studies; D002648:Child; D050171:Dyslipidemias / Q000139:chemically induced; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000503:physiopathology; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D006801:Humans; D007333:Insulin Resistance; D008060:Lipodystrophy / Q000139:chemically induced; D008297:Male; D012189:Retrospective Studies; D017539:Tunica Intima / Q000187:drug effects; D014652:Vascular Diseases / Q000139:chemically induced / Q000209:etiology* / Q000821:virology; D014664:Vasodilation / Q000187:drug effects
D044966:Anti-Retroviral Agents; D015415:Biomarkers; D017320:HIV Protease Inhibitors